Adam Scott Levy sold $130k of MLYS
CFO and Secretary at Mineralys Therapeutics, Inc.. 10,757 shares at an average of $12.06, traded Apr 11, 2025, filed Apr 15, 2025.
Score components
- +22RoleCFO
- +11Trade size$130k at market
- 0Share of holdings soldSold 4.8% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001933414-25-000046, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 11, 2025 | SOpen-market sale Common Stock10b5-1 | -10,757 | $12.06 | $130k | 215,340 | Apr 15, 2025 |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 14Weak | Mineralys Therapeutics, Inc. | Daphne Karydas director | $86k 3,000 shares | -33% | |
| 48Moderate | MLYSbuy Mineralys Therapeutics, Inc. | Srinivas Akkaraju director | $15M 588,235 shares | - | |
| 18Weak | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $230k 15,884 shares | -2% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $166k 11,366 shares | -10% | |
| 6Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $174k 11,366 shares | -10% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director, owner | $3.5M 259,259 shares | +3% | |
| 32Weak | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $187k 15,319 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.